1
Clinical Trials associated with Allogeneic anti-CD4 CAR-T (Indiana University)Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory AML as a Bridge to Allogeneic Stem Cell Transplant
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory AML. the study will evaluate safety in this patient population and also the presence of efficacy signal described by elimination of residual disease to qualify patients for stem cell transplant.
100 Clinical Results associated with Allogeneic anti-CD4 CAR-T (Indiana University)
100 Translational Medicine associated with Allogeneic anti-CD4 CAR-T (Indiana University)
100 Patents (Medical) associated with Allogeneic anti-CD4 CAR-T (Indiana University)
100 Deals associated with Allogeneic anti-CD4 CAR-T (Indiana University)